ArticleAmerican journal of translational research2026
Effects of neoadjuvant novel endocrine therapy combined with prostatic artery embolization on SII, PNI, and bRFS in patients with prostate cancer.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of neoadjuvant novel endocrine therapy combined with prostatic artery embolization (PAE) on systemic immune-inflammation index (SII), prognostic nutritional index (PNI), and biochemical recurrence-free survival (bRFS) in patients with high-risk or locally advanced prostate cancer, and to evaluate the feasibility of SII/PNI as early prognostic biomarkers.
methodsA retrospective analysis was conducted on 339 patients treated between Feb 2019 and Mar 2023, including 174 patients in the combination group (endocrine therapy + PAE) and 165 in the control group (endocrine therapy alone). PSA50/PSA90 response rates, surgical conversion rate, and changes in SII and PNI at 1 and 3 months after treatment were compared between the two groups. Kaplan-Meier analysis was used to evaluate bRFS, and time-dependent receiver operating characteristic (ROC) curves were applied to assess the predictive value of SII and PNI for 1- and 2-year bRFS.
resultsThe combination group demonstrated significantly higher PSA50/PSA90 response rates (P<0.05), higher surgical conversion rate (66.7% vs. 42.4%, P<0.001), greater reductions in SII (≥30%: 83.3% vs. 64.2%), and more pronounced PNI improvement (≥45: 82.9% vs. 69.7%, P<0.01) compared with the control group. The 1- and 2-year bRFS rates increased by 8.4% and 11.2%, respectively (P<0.05). SII and PNI measured at 3 months showed good predictive performance for bRFS, with AUC values ranging from 0.73 to 0.83. Survival analysis based on SII/PNI stratification revealed significant differences between groups (P<0.05).
conclusionThe combined regimen accelerates PSA reduction, improves surgical feasibility, and alleviates systemic inflammation and nutritional status. SII/PNI detection at 3 months may facilitate early identification of recurrence risk and guide individualized treatment adjustment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.